我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300357 我武生物

已收盘 08-12 15:00:00

{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":25,"timestamp":1786518183000,"preClose":25.39,"halted":0,"volume":9626185,"delay":0,"changeRate":-0.0154,"floatShares":484999999,"shares":524000000,"eps":0.8134,"marketStatus":"已收盘","change":-0.39,"latestTime":"08-12 15:00:00","open":25.25,"high":25.68,"low":24.97,"amount":243000000,"amplitude":0.028,"askPrice":25.01,"askSize":38,"bidPrice":25,"bidSize":420,"shortable":0,"etf":0,"ttmEps":0.8134,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786584600000},"marketStatusCode":5,"adr":0,"adjPreClose":25.39,"symbolType":"stock","openAndCloseTimeList":[[1786498200000,1786505400000],[1786510800000,1786518000000]],"highLimit":27.93,"lowLimit":22.85,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":4.85,"roa":"--","peRate":30.735186,"roe":"4.45%","epsLYR":0.7276,"committee":0.302128,"marketValue":13090000000,"turnoverRate":0.0198,"status":1,"floatMarketCap":12135000000},"requestUrl":"/m/hq/s/300357/tweets","defaultTab":"tweets","newsList":[{"id":"2658964054","title":"创新药概念持续走强，我武生物涨近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658964054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658964054?lang=zh_cn&edition=full","pubTime":"2026-08-11 13:56","pubTimestamp":1786427794,"startTime":"0","endTime":"0","summary":"8月11日，创新药概念盘中持续走强，我武生物一度涨近4%，触及25.98元/股。中泰证券表示，2026年以来，中国创新药产业逐步进入价值兑现阶段，行业逻辑由过去依赖BD事件催化，转向海外商业化、临床数据兑现及持续收入贡献，近期海外龙头药企财报持续验证中国创新资产价值，MNC对于中国创新药的战略定位逐渐提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026081100018659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1161","BK0239","159992","300357","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670713","title":"股市必读：我武生物新发布《关于获得S01D片药物临床试验申请受理通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670713","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670713?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:50","pubTimestamp":1786297820,"startTime":"0","endTime":"0","summary":"公司公告汇总：我武生物S01D片药物临床试验申请获国家药监局受理，为化学药品1类，拟用于耐药肺结核成人患者治疗，目前国内外尚无相同化学药物获批上市。公司公告汇总关于获得S01D片药物临床试验申请受理通知书的公告浙江我武生物科技股份有限公司收到国家药品监督管理局出具的《受理通知书》，S01D片药物临床试验申请已获受理。药品审评中心将在受理后六十日内决定是否同意开展临床试验，逾期未通知视为同意。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161966","title":"8月7日我武生物涨6.10%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657161966?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:48","pubTimestamp":1786092510,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日我武生物涨6.10%，收盘报24.88元，换手率3.86%，成交量18.66万手，成交额4.51亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为14.15亿元，最新净值1.5941，较上一交易日下跌0.96%，近一年下跌15.71%。鹏华医药科技股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","159938","BK1574","BK1515","BK0239","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657154836","title":"我武生物：公司始终聚焦主业，完善变应原制品产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2657154836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657154836?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:33","pubTimestamp":1786091604,"startTime":"0","endTime":"0","summary":"AI赋能上，其类脑算法、AI医生等技术是否反哺主营，协同效应怎样？希望管理层厘清从AI研发到效益转化的路径，谢谢！公司始终聚焦主业，完善变应原制品产品管线，深耕过敏性疾病诊疗领域，并逐步推动在干细胞药物、天然药物等其他领域的研发工作。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542794","title":"我武生物：猫毛膜剂药物临床试验申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657542794?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:51","pubTimestamp":1785934290,"startTime":"0","endTime":"0","summary":"2026年6月，由公司提交的“猫毛膜剂”药物临床试验申请已获得正式受理，其给药方式为舌下含服，剂型为膜剂。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884888","title":"股市必读：我武生物（300357）7月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655884888?lang=zh_cn&edition=full","pubTime":"2026-07-29 02:03","pubTimestamp":1785261797,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，我武生物报收于23.17元，下跌1.4%，换手率1.17%，成交量5.67万手，成交额1.32亿元。公司公告汇总：子公司“人脐带间充质干细胞II型注射液”临床试验申请获国家药监局正式受理，注册分类为治疗用生物制品1类，适应症为脓毒症和（或）脓毒性休克，目前国内外尚无同类获批上市产品。近日，该申请已获国家药品监督管理局正式受理。目前国内外尚无同类获批上市产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900001345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654008156","title":"我武生物最新公告：子公司人脐带间充质干细胞II型注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2654008156","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654008156?lang=zh_cn&edition=full","pubTime":"2026-07-28 17:52","pubTimestamp":1785232337,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司间接控股子公司浙江我武干细胞科技有限公司提交的“人脐带间充质干细胞II型注射液”药物临床试验申请已获国家药品监督管理局正式受理，适应症为脓毒症和(或)脓毒性休克。该药品为治疗用生物制品1类，后续需经审评、临床试验及上市许可等环节，结果存在不确定性。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。)以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800029315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650990754","title":"股市必读：我武生物（300357）7月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2650990754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650990754?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:22","pubTimestamp":1783531330,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，我武生物报收于23.15元，上涨1.09%，换手率1.7%，成交量8.23万手，成交额1.9亿元。目前，针对脓毒症和脓毒性休克的治疗策略主要局限于支持性治疗与广谱抗菌药物的应用。尽管液体复苏、血管活性药物及器官功能支持技术不断进步，但脓毒症和脓毒性休克患者的病死率及远期并发症发生率仍居高不下，临床层面仍亟待突破性治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649966706","title":"我武生物：首个在研干细胞产品适应症为脓毒症和（或）脓毒性休克","url":"https://stock-news.laohu8.com/highlight/detail?id=2649966706","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649966706?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:00","pubTimestamp":1783497634,"startTime":"0","endTime":"0","summary":"目前，针对脓毒症和脓毒性休克的治疗策略主要局限于支持性治疗与广谱抗菌药物的应用。尽管液体复苏、血管活性药物及器官功能支持技术不断进步，但脓毒症和脓毒性休克患者的病死率及远期并发症发生率仍居高不下，临床层面仍亟待突破性治疗方案。依托国家对干细胞产业的政策支持导向，结合前期充分、审慎的市场与行业调研，公司最终确立首个在研的干细胞产品适应症为脓毒症和（或）脓毒性休克。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800026773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516672","title":"我武生物涨5.02%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516672","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648516672?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:51","pubTimestamp":1782895893,"startTime":"0","endTime":"0","summary":"今日我武生物涨5.02%，收盘报24.49元。2026年4月28日，开源证券研究员余汝意,阮帅发布了对我武生物的研报《公司信息更新报告：2026Q1业绩超预期，黄花蒿花粉滴剂快速放量》，该研报对我武生物给出“买入”评级。研报中预计公司2026-2028年归母净利润分别为4.51/5.43/6.47亿元，当前股价对应PE分别为31.1/25.8/21.6倍，考虑公司黄花蒿花粉滴剂快速放量，维持“买入”评级。我武生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648562997","title":"股市必读：我武生物（300357）6月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648562997","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648562997?lang=zh_cn&edition=full","pubTime":"2026-07-01 04:48","pubTimestamp":1782852492,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，我武生物报收于23.32元，下跌1.27%，换手率2.42%，成交量11.73万手，成交额2.73亿元。董秘最新回复投资者： 公司股价低迷已经连续下跌多年，公司账上现金流充裕，希望考虑回购注销股份。交易信息汇总资金流向6月30日主力资金净流入234.64万元，占总成交额0.0%；游资资金净流出636.99万元，占总成交额0.0%；散户资金净流入402.35万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100005892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535298","title":"我武生物：累计实施的现金分红总额已超9.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647535298?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:24","pubTimestamp":1782807850,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物06月30日在投资者关系平台上答复投资者关心的问题。自上市以来，公司每年以现金方式分配的利润均大于当年归属于上市公司股东净利润的30%，回报全体股东。公司自上市以来，累计实施的现金分红总额已超9.5亿元，超过首发募集资金4倍。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000029152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322662","title":"我武生物涨10.89%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322662","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647322662?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:45","pubTimestamp":1782722742,"startTime":"0","endTime":"0","summary":"今日我武生物涨10.89%，收盘报23.62元。2026年4月28日，开源证券研究员余汝意,阮帅发布了对我武生物的研报《公司信息更新报告：2026Q1业绩超预期，黄花蒿花粉滴剂快速放量》，该研报对我武生物给出“买入”评级。研报中预计公司2026-2028年归母净利润分别为4.51/5.43/6.47亿元，当前股价对应PE分别为31.1/25.8/21.6倍，考虑公司黄花蒿花粉滴剂快速放量，维持“买入”评级。我武生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647976340","title":"创新药概念强势拉升，我武生物大涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647976340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647976340?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:42","pubTimestamp":1782704521,"startTime":"0","endTime":"0","summary":"6月29日，创新药概念强势走高，我武生物盘中一度大涨超12%。中信证券指出，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。中邮证券表示，预计我武生物26/27/28年收入分别为12.0/13.7/15.7亿元，同比增长13.3%/14.0%/14.5%；归母净利润为4.4/5.2/6.1亿元，同比增长16.6%/16.0%/17.6%，对应PE为27/23/19倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026062900013236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","BK1161","06978","BK0028","300357","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409663","title":"每周股票复盘：我武生物（300357）获猫毛膜剂临床试验受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409663","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645409663?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:58","pubTimestamp":1781981890,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，我武生物报收于21.25元，较上周的21.36元下跌0.51%。本周，我武生物6月15日盘中最高价报21.8元。本周关注点公司公告汇总：猫毛膜剂临床试验申请获国家药监局受理。该产品为治疗用生物制品1类，拟用于猫毛皮屑致敏相关的变应性鼻炎成人患者，剂型为膜剂，给药方式为舌下含服。目前尚无其他企业取得该品种的药品注册证书。后续需经临床试验审评、各期临床试验及上市许可申请等环节，结果存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644098477","title":"我武生物：获得猫毛膜剂临床试验申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2644098477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644098477?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:57","pubTimestamp":1781773065,"startTime":"0","endTime":"0","summary":"我武生物(300357.SZ)公告称，公司获得国家药监局《受理通知书》，其提交的“猫毛膜剂\"药物临床试验申请已正式受理。该产品为治疗用生物制品1类，适应症用于猫毛皮屑致敏相关的变应性鼻炎的成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026061800029400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643783448","title":"股市必读：我武生物（300357）6月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2643783448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643783448?lang=zh_cn&edition=full","pubTime":"2026-06-16 03:35","pubTimestamp":1781552113,"startTime":"0","endTime":"0","summary":"截至2026年6月15日收盘，我武生物报收于21.2元，下跌0.75%，换手率2.31%，成交量11.19万手，成交额2.36亿元。董秘最新回复投资者： 董秘您好:公司业务这么好，现金流又充是股票近期跌这么多，近期有没有回购计划？？？当日关注点交易信息汇总：6月15日主力资金净流入55.21万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600004484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642228866","title":"我武生物最新公告：撤回“人脐带间充质干细胞II型注射液”药物临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2642228866","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642228866?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:22","pubTimestamp":1781169764,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司间接控股子公司浙江我武干细胞科技有限公司撤回“人脐带间充质干细胞II型注射液”药物临床试验申请。撤回原因为需完善部分药学研究，待完善后将尽快重新提交申请。该事项预计不会对公司生产经营与当期业绩产生重大影响。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。过敏原特异性免疫治疗 ，即脱敏治疗，是世界卫生组织推荐的唯一可能影响过敏性疾病自然进程的“对因治疗”方法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100027361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639533613","title":"股市必读：我武生物（300357）5月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2639533613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639533613?lang=zh_cn&edition=full","pubTime":"2026-05-29 02:49","pubTimestamp":1779994149,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，我武生物报收于22.13元，下跌1.64%，换手率1.37%，成交量6.63万手，成交额1.47亿元。董秘最新回复投资者： 董秘您好！公司主要产品“畅迪”贮存条件严格且为单螨、滴剂，便利性和疗效均存在短板。当日关注点来自交易信息汇总：5月28日主力资金净流出280.75万元，游资资金净流入644.69万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900002321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669987","title":"我武生物：屋尘螨膜剂目前处于II期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638669987?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:21","pubTimestamp":1779960067,"startTime":"0","endTime":"0","summary":"该产品是公司主导产品“粉尘螨滴剂”的升级产品，其给药方式为舌下含服，剂型为膜剂，膜剂具有良好的舌下吸附性、更好的给药准确性、更优良的患者用药依从性。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800030279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786551607558,"stockEarnings":[{"period":"1week","weight":0.0457},{"period":"1month","weight":0.0745},{"period":"3month","weight":0.0234},{"period":"6month","weight":-0.0821},{"period":"1year","weight":-0.015},{"period":"ytd","weight":-0.0956}],"compareEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0727},{"period":"6month","weight":-0.0484},{"period":"1year","weight":0.0786},{"period":"ytd","weight":-0.0088}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35569人(较上一季度增加22.16%)","perCapita":"13647股","listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","registeredCapital":"52358万元","survey":"　　浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒、屋尘螨皮肤点刺诊断试剂盒、黄花蒿花粉变应原皮肤点刺液、白桦花粉变应原皮肤点刺液、葎草花粉变应原皮肤点刺液、悬铃木花粉变应原皮肤点刺液、德国小蠊变应原皮肤点刺液、猫毛皮屑变应原皮肤点刺液。公司被浙江省经济和信息化厅、浙江省财政厅、国家税务总局浙江省税务局于2024年12月联合认定为高新技术企业。","listedPrice":20.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}